To investigate how semaglutide affects different causes of death, researchers analyzed data from a trial of about 17,000 adults that ran from 2021 through 2023. The trial enrolled middle-aged adults who are overweight or obese, have cardiovascular disease and do not have diabetes.
Of the 833 deaths, 58% were related to cardiovascular issues and 42% were not. Among deaths not caused by cardiovascular conditions, infection was the most common cause, which occurred at a higher rate among the placebo group compared to semaglutide users.
“Semaglutide did not reduce incident COVID-19; however, among participants who developed COVID-19, fewer participants treated with semaglutide had COVID-19–related serious adverse events or died of COVID-19” compared to the placebo cohort, the researchers found.
Semaglutide patients also had lower rates of all-cause deaths, which the researchers associated with the weight loss drug reducing obesity-related health complications.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.